Report Medicaid Managed Care Pharmacy & Medication ‘Issues’ to NYS DOH Pharmacy Program by describing the issue in detail in an email to: PPNO@Health.state.ny.US.
Medical Providers, Patient Navigators, Case Managers, Care Managers, Advocates, Pharmacists, Patients and Care Givers are all encouraged to report issues so that the system can be improved.
Related Articles
-
Hep C Advocates – Take action against the Hep C epidemic!
NASTAD has issued a Call to Action for an urgent response to the nation's hepatitis C epidemic.
-
Sign On | Ensure HCV Testing is Incorporated into Medicare Visits (Deadline April 30)
Sign the letter urging Secretary Sebelius to ensure that Medicare incorporates hepatitis C screening into the Welcome to Medicare exam and the Medicare annual wellness visit.
-
Join the Hep B Storytelling Project (Hep B Foundation)
StoryCenter’s “Digital Storytelling Workshop” brings a small group of people together to share true personal stories from their lives, as short digital videos.
-
NYC Council Viral Hepatitis Initiative
In 2014, NYC Council established the Viral Hepatitis Initiative, which has served to establish and sustain four programs to build community health organization capacity to prevent, identify, manage and treat hepatitis B and C.
-
NYS Attorney General to Investigate Insurers Over Hep C Drug Coverage
The NYS attorney general has asked 16 health insurance companies for information on their coverage of Hepatitis C treatments, amid concerns that some companies are restricting coverage of the medications.
-
Empire Liver Foundation | Hepatitis Clinical Training Program
The Hepatitis Clinical Training Program aims to increase the number of NYC clinicians who identify and and care for hepatitis B and C according to national guidelines
-
NYS Hepatitis C Elimination Summit
On February 7, 2017, government representatives; medical providers; harm reduction and social service providers; and community advocates came together in Albany for the nation’s first Hep C Elimination Summit.
-
FDA Approves Zepatier for Treatment of Hep C
The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
